Small Molecule Inhibitors Targeting Paxillin-Alpha4 Integrin Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing α4 integrin antagonists used for treating autoimmune diseases are associated with hematopoietic and developmental toxicities, and can cause progressive multifocal leukoencephalopathy due to complete blockade of α4 integrin function, while partial inhibition of integrin signaling may not effectively impair mononuclear leukocyte recruitment to inflammatory sites.
Innovation Solution
Development of novel compounds that inhibit the interaction of paxillin or its paralogues with α4 integrin or its binding partners, specifically targeting signaling events downstream of the paxillin-α4 interaction to selectively impair mononuclear leukocyte recruitment without causing hematopoietic or developmental toxicities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing α4 integrin antagonists are used to treat autoimmune diseases, then mononuclear leukocyte recruitment to inflammatory sites is inhibited, but hematopoietic and developmental toxicities occur due to complete blockade of α4 integrin function
Solution Approach 1:
The patent applies local quality by designing compounds that selectively inhibit specific signaling pathways (paxillin-α4 interaction) rather than blocking all α4 integrin functions. This localized inhibition targets inflammatory cell recruitment while preserving essential functions in hematopoiesis and development, thereby achieving therapeutic effectiveness without the associated toxicities
Solution Approach 2:
The invention segments the α4 integrin function into distinct pathways: signaling functions (which are inhibited) and ligand binding functions (which remain intact). This segmentation allows selective blockade of pathological processes while maintaining physiological functions, resolving the contradiction between therapeutic effectiveness and safety
2Productivity
If α4 integrin function is completely blocked to inhibit mononuclear leukocyte recruitment, then inflammatory disease symptoms are reduced, but adverse effects on development and hematopoiesis occur
Solution Approach 1:
The patent implements partial action by achieving sufficient inhibition of inflammatory cell recruitment through selective blockade of the paxillin-α4 interaction, without requiring complete blockade of all α4 integrin functions. This partial inhibition maintains the therapeutic anti-inflammatory effect while avoiding the toxicities associated with complete function loss
3Reliability
If anti-α4 antibodies are used to block integrin-ligand interactions, then lymphocyte and monocyte recruitment is inhibited, but mechanism-based toxicities such as defects in placentation, heart development, and hematopoiesis occur
Solution Approach 1:
The invention extracts and targets only the specific paxillin-α4 interaction component that is responsible for pathological inflammatory cell recruitment. By isolating this specific interaction as the therapeutic target, the patent achieves anti-inflammatory effectiveness while leaving other essential α4 integrin functions (such as those required for placentation, heart development, and hematopoiesis) intact
Data Source
AI summary
The present invention is directed to novel compounds that are able to inhibit the interaction of paxillin or its paralogues, including leupaxin or Hic-5, with alpha.4 integrin or its binding partners that regulate signaling events downstream of the paxillin-.alpha.4 interaction. The present invention further relates to methods for therapeutic use of such compounds and pharmaceutical compositions of such compounds for the treatment of a disease or condition.